Omniome Stock

omniome.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $153.29MM

Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy.

Register To Buy and Sell Shares

For more details on financing and valuation for Omniome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Omniome’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Omniome.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

David Mullarkey
Chief Executive Officer, President & Board Member
Kelly Perez
Senior Vice President of Finance
Arnold Oliphant Ph.D
Chief Technology Officer
Ken Song MD
Executive Chairman
Melissa Tosca
Director, Finance and Accounting

Board Members

David Cruikshank
Kim Kamdar Ph.D
Dan Zabrowski Ph.D
Ken Song MD
Michael Yi
Boris Nikolic MD
Biomatics Capital
David Mullarkey

News Highlights

Omniome Raises $60M in Series C Financing | FinSMEs
Omniome, Inc., a San Diego, CA-based developer of an innovative DNA sequencing platform, raised an additional $60m and completed the Series C funding
Updated on: Apr 20, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.